WSI, a pharmaceutical and medical device distribution specialist, is strengthening its competitiveness in the surgical robot business. The company aims to create synergy in the surgical robot sector with its overseas partner, China’s Shengjian Tech Group.
On the 11th, WSI announced that its subsidiary Easy Medibot and Shengjian Tech (LifeTech Scientific Corp) Group will collaborate on the development and commercialization of surgical robots. The three companies plan to cooperate to expand the surgical robot business and pioneer the global market.
WSI and Easy Medibot will register and sell the non-invasive cancer treatment support robot 'Epione®,' for which Shengjian Tech’s subsidiary holds sales rights in the Asian region, in the domestic medical device market.
Shengjian Tech will cooperate in clinical trials, medical device registration, sales, and marketing in China for the obstetrics and gynecology laparoscopic surgical robot 'U-Bot,' currently being developed by Easy Medibot.
Epione is a percutaneous cancer treatment robotic system developed and manufactured by the French medical robot company Quantum Surgical. It utilizes a robotic arm, navigation system, and camera. It has received European CE certification and U.S. FDA approval.
U-Bot is a uterus position control assist robot with precise drug injection capabilities. It is being developed for use in laparoscopic and obstetrics and gynecology surgeries, including hysterectomy, myomectomy, oophorectomy, ovarian cystectomy, and pelvic and para-aortic lymphadenectomy. It is expected to improve surgical accuracy and safety and replace tasks that do not require specialized medical personnel, potentially expanding its application to various medical fields in the future.
A WSI representative stated, "We are establishing a multifaceted cooperative system with Shengjian Tech, which possesses leading technology in the medical robot field. By actively utilizing each company’s R&D capabilities and sales networks, we will succeed in commercializing surgical robots in the near future."
Shengjian Tech, listed on the Hong Kong Stock Exchange, holds the number one market share in Europe for structural heart disease-related fields. It manufactures and sells devices for congenital and structural heart diseases, peripheral vascular diseases, and surgical vascular treatments in over 100 countries worldwide.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
